本帖最后由 老马 于 2013-3-13 13:43 编辑 3 m( e5 Y) W, r, g
/ i! ~5 c. J3 L) C健择（吉西他滨）+顺铂+阿瓦斯汀* h8 b$ I8 z& B. g0 z' z% ]
Gemzar +Cisplatin + Avastin
' d" t7 V3 ?+ h" bhttp://annonc.oxfordjournals.org/content/21/9/1804.full3 {+ M& z# o/ y/ B, i$ l- _. |7 x
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) 4 t$ `/ E5 q1 G
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. 4 {2 c# {! @6 t0 R
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
@7 q5 [5 u- C1 l6 j
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 250)
8 k' A0 G" x9 m6 d5 z华为网盘附件：
/ \( h" m! _6 @% L9 Y- f【华为网盘】ava.JPG
6 J1 \: n* q) F, p- i- ] |
显身卡
